NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Coherus BioSciences Inc (NASDAQ: CHRS)

 
CHRS Technical Analysis
5
As on 21st Nov 2024 CHRS STOCK Price closed @ 1.10 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.23 & Strong Sell for SHORT-TERM with Stoploss of 4.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CHRSSTOCK Price

Open 1.07 Change Price %
High 1.11 1 Day 0.31 39.24
Low 1.01 1 Week 0.32 41.03
Close 1.10 1 Month 0.06 5.77
Volume 1655545 1 Year -4.29 -79.59
52 Week High 5.45 | 52 Week Low 0.67
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
NVDA 146.67 0.53%
AKTS 0.10 11.11%
WORX 2.12 116.33%
QUBT 4.76 29.35%
LMDX 0.02 0.00%
SMCI 29.70 5.06%
MSTR 397.28 -16.16%
MARA 23.81 22.17%
CRNC 5.83 106.74%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
LAZR 10.24 1164.20%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
FBRX 15.64 163.74%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
PRFX 3.10 131.34%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
ZVZZT 11.30 -64.82%
MILEW 0.06 -53.85%
MNTSW 0.01 -50.00%
LOTZW 0.01 -50.00%
LIXTW 0.02 -50.00%
 
 
CHRS
Daily Charts
CHRS
Intraday Charts
Whats New @
Bazaartrend
CHRS
Free Analysis
 
CHRS Important Levels Intraday
RESISTANCE1.29
RESISTANCE1.23
RESISTANCE1.19
RESISTANCE1.15
SUPPORT1.05
SUPPORT1.01
SUPPORT0.97
SUPPORT0.91
 
CHRS Forecast November 2024
4th UP Forecast3.59
3rd UP Forecast2.79
2nd UP Forecast2.3
1st UP Forecast1.8
1st DOWN Forecast0.4
2nd DOWN Forecast-0.1
3rd DOWN Forecast-0.59
4th DOWN Forecast-1.39
 
CHRS Weekly Forecast
4th UP Forecast4.63
3rd UP Forecast3.50
2nd UP Forecast2.80
1st UP Forecast2.10
1st DOWN Forecast0.10
2nd DOWN Forecast-0.60
3rd DOWN Forecast-1.30
4th DOWN Forecast-2.43
 
CHRS Forecast2024
4th UP Forecast10.68
3rd UP Forecast7.61
2nd UP Forecast5.71
1st UP Forecast3.81
1st DOWN Forecast-1.61
2nd DOWN Forecast-3.51
3rd DOWN Forecast-5.41
4th DOWN Forecast-8.48
 
 
CHRS Other Details
Segment EQ
Market Capital 1275689728.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CHRS Address
CHRS
 
CHRS Latest News
 
Your Comments and Response on Coherus BioSciences Inc
 
CHRS Business Profile
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service